EAACI Congress 2025
BackFT05 - Immunotherapy from patient and epidemiological study perspective
Friday 13 Jun, 15:00 PM -
16:30 PM Glasgow, United Kingdom
Dochart 2
Flash Talks
15:00
Positive impact on quality of life with a depigmented-polymerized house dust mite extract immunotherapy
15:07
Impact of allergic rhinitis activity on the effect of 300IR house dust mite sublingual immunotherapy tablet in adolescent patients
15:14
Correlation between subjective and objective parameters in house dust mite nasal allergen challenge
15:21
Profile of patients treated with the 300IR liquid sublingual immunotherapy for cat allergy and perception of treatment effect: Results from a French survey
15:28
Disease burden of allergic rhinitis in children : results of the ORACLE survey among paediatricians
15:35
Allergen-Specific Ige Assessment Across China: A Nationwide Cross-Sectional Study
15:42
Safety and compliance of sublingual immunotherapy with house dust mite extract in patients with atopic dermatitis for 1 year
15:49
Patient-reported outcomes after 5 years of oral immunotherapy for peanut allergy: results from the BOPI (Boiled Peanut Oral Immunotherapy) study
15:56
Steroid sparing effect of liquid sublingual immunotherapy in patients with allergic rhinitis with or without asthma in the real-world EfficAPSI study
16:03
The Efficacy and Safety of Ultra-Rush Subcutaneous Immunotherapy for Allergic Rhinitis
16:10
A multi center retrospective study of the incidence of systemic reactions, spontaneous abortions and pre-term birth in pregnant women who undergo specific immunotherapy for Hymenoptera venom because of severe allergic reactions to Hymenoptera venom
16:17
Characterisation of patients with significant treatment effect of intralymphatic immunotherapy
